AstraZeneca Coverage Initiated at UBS AG (AZN)
Equities research analysts at UBS AG began coverage on shares of AstraZeneca (LON:AZN) in a research note issued to investors on Friday, ARN reports. The firm set a “buy” rating on the stock.
A number of other firms have also recently commented on AZN. Analysts at S&P Equity Research upgraded shares of AstraZeneca to a “hold” rating in a research note to investors on Friday. They now have a GBX 3,700 ($60.69) price target on the stock, up previously from GBX 2,900 ($47.56). Separately, analysts at Bryan Garnier & Cie reiterated a “neutral” rating on shares of AstraZeneca in a research note to investors on Thursday. They now have a GBX 3,640 ($59.70) price target on the stock. Finally, analysts at Deutsche Bank reiterated a “hold” rating on shares of AstraZeneca in a research note to investors on Thursday. They now have a GBX 3,600 ($59.05) price target on the stock. Thirteen equities research analysts have rated the stock with a sell rating, seventeen have issued a hold rating and four have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average target price of GBX 3,128.75 ($51.32).
Shares of AstraZeneca (LON:AZN) traded up 2.23% on Friday, hitting GBX 3652.00. The stock had a trading volume of 2,673,243 shares. AstraZeneca has a 52-week low of GBX 2895.00 and a 52-week high of GBX 3669.50. The stock has a 50-day moving average of GBX 3526. and a 200-day moving average of GBX 3301.12. The company’s market cap is £45.760 billion.
AstraZeneca PLC (LON:AZN) is a global biopharmaceutical company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.